London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru

London, July 5 - Breast cancer patients, who are overweight or obese, might benefit less from treatment with docetaxel, a common chemotherapy dru